Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29
Stock Information for Fortress Biotech Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About Fortress Biotech Inc.
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea
Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights